{"page_content": "A FEW HIGHLIGHTS INCLUDE:\n\u2022 The establishment of ApellisAssistTM, our patient \nsupport program, with the goal of ensuring \nthat every person prescribed our medicine has \naccess, regardless of the ability to pay, through \none of the ApellisAssist financial assistance \nprograms.\n\u2022 The creation of a diversity, equity, and inclusion \n(DEI) program at Apellis aimed at developing \nand implementing a DEI strategy that aligns \nwith our commitment to foster a sense of \nbelonging and safety for all employees. We are \nalso evaluating DEI-focused policies across our \nbusiness.\n\u2022 The launch of Project Apollo, an updated \nquality management system, focused on \nhelping our teams efficiently drive compliance, \nproduct quality, innovation, and patient safety \nacross the company.Our executive team and Board of Directors \nsupport the continued growth of our sustainability \nefforts. We believe that by doing so, it will \nstrengthen our ability to advance revolutionary \nscience, deliver important new medicines to \npatients, and make a difference in people\u2019s lives \nfor many years to come. We recognize there is a \nlot of work to be done. I am excited by our initial \nprogress and grateful to all Apellis employees as \nwe seek to become a sustainable company and \ndeliver on our vision. \nCedric Francois, M.D., Ph.D.  \nCO-FOUNDER & CHIEF EXECUTIVE OFFICER/PRESIDENT\nWe aim to operate with high ethical \nstandards and ensure our decisions and \nactions are guided by our corporate values. 2\nAPELLIS SUSTAINABILITY REPORT 2021", "metadata": {"source": "NASDAQ_APLS_2021.pdf", "page": 3, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}